These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 25337673)

  • 41. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.
    Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME
    Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
    Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling.
    Peter SC; Mannu J; Mathur PP
    Methods Mol Biol; 2017; 1549():221-229. PubMed ID: 27975295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IQGAP1 binds the Axl receptor kinase and inhibits its signaling.
    Gorisse L; Li Z; Hedman AC; Sacks DB
    Biochem J; 2018 Oct; 475(19):3073-3086. PubMed ID: 30185434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
    Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
    Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
    Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
    Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
    Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E
    Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.
    Paccez JD; Vogelsang M; Parker MI; Zerbini LF
    Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Axl-dependent signalling: a clinical update.
    Korshunov VA
    Clin Sci (Lond); 2012 Apr; 122(8):361-8. PubMed ID: 22187964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
    Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
    Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
    Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S
    Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
    Dransfield I; Farnworth S
    Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
    Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Axl kinase as a key target for oncology: focus on small molecule inhibitors.
    Feneyrolles C; Spenlinhauer A; Guiet L; Fauvel B; Daydé-Cazals B; Warnault P; Chevé G; Yasri A
    Mol Cancer Ther; 2014 Sep; 13(9):2141-8. PubMed ID: 25139999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.